This book concerns HIV prevention. In it the authors argue that until the world focuses its attention on the social issues carried and revealed by AIDS, it is unlikely that HIV transmission will be eradicated or even significantly reduced. The book argues that we are currently witnessing the remedicalisation or the continuing biomedicalisation of HIV prevention, which began in earnest after the development of successful HIV treatment, and that this biomedical trajectory continues with the increasing push to use HIV treatments as prevention, undermining what has been in many countries a successful prevention response. This wide-ranging study argues that HIV prevention involves enabling people and communities to discuss sex, sexuality and drug use and, informed by these discussion, devising locally effective strategies for promoting safe sexual and drug injection practices.

Biomedical Advances in HIV Prevention: Social and Behavioral Perspectives Lisa A. Eaton and Seth C. Kalichman, editors Three decades into the epidemic, a great deal is known about HIV and its transmission, more people are living with the disease, and the virus is no longer seen as a death sentence. But new people continue to be infected with HIV each year, making prevention strategies that are medically effective and behaviorally engaging as urgent a priority as ever. Biomedical Advances in HIV Prevention: Social and Behavioral Perspectives assembles the latest improvements, barriers to implementation, and possibilities for--and challenges to--future progress. Innovations such as pre-exposure prophylaxis (antiretroviral regimens for the high-risk uninfected) and treatment as prevention (early use of ART to reduce infectiousness of new patients) are examined, as are current findings on ongoing prevention and treatment concerns. Contributors illuminate the complex realities entailing adherence, pointing out technological, behavioral, and cultural roadblocks as well as opportunities to significantly reduce infection rates. Detailed up-to-the-minute coverage includes: Prevention services for persons living with HIV Adherence to HIV treatment as prevention and pre-exposure prophylaxis Advocating for rectal microbicides and safe lubricants Mental health and substance use in the scale-up of HIV prevention Risk compensation in response to HIV prevention Implementing biomedical HIV prevention advances: reports from South Africa, Uganda, Australia, Thailand, United States, Ecuador, and Peru Researchers, practitioners, and policy makers working in the fields of HIV/AIDS and public health will look toward Biomedical Advances in HIV Prevention: Social and Behavioral Perspectives as both a means for developing and assessing current programs and a blueprint for the next generation of prevention efforts.

Europe's "Black Death" contributed to the rise of nation states, mercantile economies, and even the Reformation. Will the AIDS epidemic have similar dramatic effects on the social and political landscape of the twenty-first century? This readable volume looks at the impact of AIDS since its emergence and suggests its effects in the next decade, when a million or more Americans will likely die of the disease. The Social Impact of AIDS in the United States addresses some of the most sensitive and controversial issues in the public debate over AIDS. This landmark book explores how AIDS has affected fundamental policies and practices in our major institutions, examining: How America's major religious organizations have dealt with sometimes conflicting values: the imperative of care for the sick versus traditional views of homosexuality and drug use. Hotly debated public health measures, such as HIV antibody testing and screening, tracing of sexual contacts, and quarantine. The potential risk of HIV infection to and from health care workers. How AIDS activists have brought about major change in the way new drugs are brought to the marketplace. The impact of AIDS on community-based organizations, from volunteers caring for individuals to the highly political ACT-UP organization. Coping with HIV infection in prisons. Two case studies shed light on HIV and the family relationship. One reports on some efforts to gain legal recognition for nonmarital relationships, and the other examines foster care programs for newborns with the HIV virus. A case study of New York City details how selected institutions interact to give what may be a picture of AIDS in the future. This clear and comprehensive presentation will be of interest to anyone concerned about AIDS and its impact on the country: health professionals, sociologists, psychologists, advocates for at-risk populations, and interested individuals.

The basic biology of the HIV virus provides a model for a more general understanding of retroviruses, and the worldwide epidemic of AIDS makes research into the disease process and potential therapies among the most critical in biomedical science. This book explores work on the molecular biology of HIV, host-virus interactions, host immune responses, HIV transmission, and more.

Essential reading for social and medical scientists and all those interested in infectious diseases and public health, AIDS and the Twenty-First Century examines the social and economic origins and impacts of the HIV/AIDS epidemic. HIV/AIDS is not only a medical problem. It is an indication of the scale of the global crisis in public health. Accessibly written, this book is necessary reading for policymakers, students and all those who are concerned about the relationship between poverty, inequality and infectious diseases.

The United States has spent two productive decades implementing a variety of prevention programs. While these efforts have slowed the rate of infection, challenges remain. The United States must refocus its efforts to contain the spread of HIV and AIDS in a way that would prevent as many new HIV infections as possible. No Time to Lose presents the Institute of Medicine's framework for a national prevention strategy.

These Good Participatory Practice guidelines aim to provide systematic guidance on the roles and responsibilities of entities funding and conducting biomedical HIV prevention trials towards participants and their communities. Such entities include investigators, research staff, pharmaceutical industry sponsors, foundations, government-supported research networks, non-governmental research sponsors, and all others involved in designing, financing, and executing clinical trials research.